The World Health Organization (WHO) has officially
recommended two groundbreaking immunization tools aimed at protecting infants
from Respiratory Syncytial Virus (RSV)—a leading cause of
acute lower respiratory infections in young children. These new vaccines are
expected to significantly reduce hospitalizations and deaths,
particularly in low- and middle-income countries, where 97%
of RSV-related deaths occur.
A New Era of RSV Prevention
WHO's recommendations include:
· A
maternal vaccine administered to pregnant women in their third
trimester, offering newborns immediate protection.
· A long-acting antibody injection for infants, which begins working within a week of administration and provides at least five months of immunity.